Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients With Hormone Receptor-Negative Metastatic Breast Cancer
Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2011.03.021
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2011
Authors
Publisher
Elsevier BV